Taken from the lecture recordings, not the slides. He stated his own emphasis marker out loud, then said “notable” 45 times in Lecture 1 alone and gave 22 explicit instructions to star or underline something. Four standing rules, 4 complete test-question shapes he handed over, 48 quotes, each with its timestamp.
tools/check_pharm_wood.py before this page is written, matching the uncorrected
text so the check cannot be fooled by the cleanup.“So anytime I say like, hey, note this, this is really notable — that’s something you should probably be starring. Because again, think about those kinds of things and write test questions, right?”
“Anytime we see QT prolongation, you should star that, underline it, whatever you need to do.”
… and again: “… that causes QT prolongation — star it, underline it, it’s good to know.”
It spans three classes on this exam: macrolides (worse with class Ia and III antiarrhythmics and with electrolyte abnormalities), fluoroquinolones, and posaconazole (whose QT risk runs mostly through the hypokalemia and hypomagnesemia it causes). He flagged it the first time it appeared and again three minutes later.
What he actually taught around it: the QT interval is how long the ventricle takes to repolarize, and it lengthens because the drug blocks the potassium channel that lets K+ out of the cell — the slide names it the hERG channel. A long enough QT degenerates into torsades de pointes, French for “twisting of the points”, a ventricular arrhythmia he called not compatible with life. Three things multiply the risk: a congenital long QT, several QT-prolonging drugs stacked together, and electrolyte disturbance — a single Z-Pak in a healthy person did not worry him. The treatment of choice for torsades is magnesium sulfate, two grams, which he called the “two gram slam” and said was worth remembering.
“Again, anytime you see MRSA coverage — star it, highlight it, underline it, right? Pseudomonas, C. diff, those are all things you want to be thinking about. Kind of big notable bugs.”
On this exam the agents with MRSA coverage are vancomycin, linezolid, clindamycin, ceftaroline, tetracyclines and tigecycline (not VRE), plus topical mupirocin. He introduced Staphylococcus aureus early as “a very notable bug… especially when we talk about the dreaded MRSA.”
“This is also an example of a drug that is teratogenic. That means it can cause harm to a fetus, and so you would need to check a pregnancy prior to giving this. So anytime we see a teratogenic drug, also note that, because it can be very significant — especially because a lot of patients, when they’re first pregnant, may not know it, and they can go weeks before they know.”
The teratogens on this exam are itraconazole, fluconazole and voriconazole (the last two “teratogenic in animals”), plus isotretinoin, which he called extremely teratogenic in Lecture 2 and placed in pregnancy category X — his definition: “no situation in which the benefits of this drug outweigh the risk to a developing fetus,” with effects running from malformation to fetal death. Topical retinoids are avoided in pregnancy as well, and tetracyclines in the second and third trimesters — stated as an outright contraindication when he restated it in Lecture 2. The action he wants is the same every time: check a pregnancy test before you prescribe to anyone of childbearing potential.
“For whatever reason, even though I highlight it every time I talk about this drug, I always talk about which of these drugs can cause rebound nasal stuffiness, or rebound ocular redness, when used for more than three days. And for whatever reason, students have a really tough time with this one… if you get it wrong on the test, which I hope you don’t, you’ll be able to say, oh, he did warn me about that. I should have underlined it, starred it, whatever.”
This is oxymetazoline (Afrin) and the condition is rhinitis medicamentosa — rebound congestion from overstimulated alpha receptors downregulating, so the congestion returns when the drug stops. He notes it needs a taper, not an abrupt stop. Worth noting: he flagged this harder than any other single fact in Lecture 3.
“If you ever see a test question — ever, ever, ever, on the PANCE or anywhere else — where it says, hey, the patient was coming in for a pneumonia and they were at a hotel and the AC unit was contaminated, it’s always Legionella.”
He then gave the reason it is a stock stem: Legionnaires’ disease was discovered from Legionella contaminating an air-conditioning unit during an American Legion convention at a hotel. He called it a classic scenario. Legionella is an atypical, so the answer is a macrolide, a tetracycline or a respiratory fluoroquinolone.
“If I said, okay, test question — a patient was getting an antibiotic infused and all of a sudden they’re red from head to toe and complaining of some itching, medication was infused over 30 minutes. What’s most likely to cause that?”
He answered it himself: vancomycin infusion syndrome — and gave the fix, which is running it over about two hours rather than 30 minutes. The infusion RATE is the whole answer; this is not an allergy.
“This can also be used for things like toxin-mediated diseases, because the clindamycin can actually bind to the toxin. So if you ever hear of toxic shock syndrome — or the classic sort of presentation is, a girl left in a tampon for too long and then all of a sudden gets septic shock from that, due to toxins being released by bacteria — clindamycin can be utilized for that.”
He calls it “a unique sort of point” for clindamycin. The mechanism is the thing to carry: it binds the toxin, which is why it beats an agent that merely kills the organism in a toxin-mediated illness.
“If I say on a test question — hey, they’re presenting for treatment for acne, they say they use benzoyl peroxide but it’s just that their skin got so irritated they didn’t want to continue it. What do you go to next? Topical retinoids kind of makes sense from that standpoint.”
A next-step stem rather than a diagnosis one. He set it up by saying that if the patient has not tried anything yet, starting with benzoyl peroxide is perfectly reasonable — so the stem turns on what they already failed and why.
“If I spend a lot of time talking about something, I’m probably thinking about that when writing test questions. So you can use that sometimes to get clues on what maybe I’m thinking about for specific questions.”
“Focus on categorizing these meds into as big of a band as you can for each group. Don’t memorize each individual side effect for every individual penicillin. Just know that all penicillins have the same side effects, they all have the same mechanism. The differences between them would be things like, which one has anti-pseudomonal coverage? Which ones are specifically for MSSA?”
“For the beta blockers, generally speaking, if the beta blocker starts with the letter N through Z, it is considered a non-selective beta blocker… A through M as in Mary are generally going to be considered the cardioselective beta blockers.”
“Am I going to be so mean on the test that I would have you differentiate nebivolol? No, that’s kind of an exception to the rule. I’d rather you get the rule down first and then we can focus on the exceptions… I’m not going to try to be sneaky with you.”
But he did name the two exceptions he would focus on: labetalol and carvedilol, because they carry additional alpha-1 blockade and are also non-selective.
| Topic | Time spent | From |
|---|---|---|
| Antifungals | 20 min | 1:52:58 to 2:13:09 |
| Penicillins | 20 min | 23:33 to 43:43 |
| Antibiotic principles & resistance | 14 min | 9:28 to 23:33 |
| Cephalosporins | 14 min | 43:43 to 57:15 |
| Antivirals | 11 min | 2:13:09 to 2:24:33 |
| Macrolides | 9 min | 1:08:45 to 1:18:13 |
| Fluoroquinolones | 9 min | 1:31:48 to 1:40:36 |
| Vancomycin | 8 min | 1:00:45 to 1:08:45 |
| Tetracyclines | 6 min | 1:18:13 to 1:24:16 |
| Aminoglycosides | 5 min | 1:24:16 to 1:29:25 |
| Trimethoprim/sulfamethoxazole | 5 min | 1:42:42 to 1:47:32 |
| Metronidazole | 4 min | 1:47:32 to 1:51:25 |
| Carbapenems | 3 min | 58:09 to 1:00:45 |
| Linezolid & daptomycin | 2 min | 1:29:25 to 1:31:48 |
| Clindamycin | 2 min | 1:40:36 to 1:42:42 |
| Polymyxins | 2 min | 1:51:25 to 1:52:58 |
| Wrap-up & questions | 1 min | 2:24:33 to 2:25:32 |
| Monobactams | 1 min | 57:15 to 58:09 |
| Topic | Time spent | From |
|---|---|---|
| Acne — pathophysiology | 14 min | 12:49 to 26:35 |
| Acne — systemic therapy | 13 min | 38:42 to 51:54 |
| Acne — topical therapy | 12 min | 26:35 to 38:42 |
| Topical drug delivery & vehicles | 10 min | 2:42 to 12:49 |
| Topical corticosteroids | 10 min | 54:18 to 1:04:13 |
| Topical anti-infectives | 8 min | 1:04:13 to 1:11:46 |
| Atopic dermatitis | 2 min | 51:54 to 54:18 |
| Topic | Time spent | From |
|---|---|---|
| Adrenergic agonists | 45 min | 1:14:37 to 1:59:47 |
| ANS organization & receptors | 21 min | 0:31 to 21:09 |
| Cholinergic agonists | 17 min | 21:09 to 38:02 |
| Antimuscarinics | 14 min | 49:11 to 1:03:13 |
| Beta blockers | 12 min | 2:03:56 to 2:16:09 |
| Neuromuscular blockers | 11 min | 1:03:13 to 1:14:37 |
| Cholinesterase inhibitors | 11 min | 38:02 to 49:11 |
| Q&A and study advice | 8 min | 2:16:09 to 2:24:30 |
| Adrenergic antagonists | 4 min | 1:59:47 to 2:03:56 |
| Drug or topic | What he flagged | Where |
|---|---|---|
| Staphylococcus aureus | “A very notable bug… especially when we talk about the dreaded MRSA.” | L1 28:40 |
| Pseudomonas | “A really important bug from the gram-negative category” — watch for which agents carry anti-pseudomonal cover. | L1 42:41 |
| Aztreonam | Notable because there is no documented cross-sensitivity with beta-lactams — usable in a true penicillin allergy. | L1 57:45 |
| Imipenem | “A very notable unique side effect just for imipenem” — seizures, and the first time seizures appear in the lecture. | L1 1:00:16 |
| Vancomycin, route | “So note that, star that” — oral vancomycin for C. difficile; IV only treats systemic infection and will not touch gut C. diff. | L1 1:02:25 |
| Macrolides | First appearance of QT prolongation — “this is notable, this is the first time we’re seeing this too.” | L1 1:13:38 |
| Macrolides | They inhibit CYP3A4 — he calls 3A4 the one that matters for this exam. | L1 1:16:30 |
| Tetracyclines | “Good gram positive coverage that actually does cover MRSA, so that’s notable.” | L1 1:19:18 |
| Tetracyclines | They chelate cations — iron and calcium. Separate the doses. | L1 1:20:07 |
| Tetracyclines | Photosensitivity — “particularly notable for Florida.” | L1 1:20:56 |
| Tetracyclines | Teeth discoloration and skeletal effects, because it binds calcium in developing bone — avoid under 8 and in later pregnancy. | L1 1:21:19 |
| Tigecycline | Adjust for hepatic dysfunction — the opposite of most drugs in this lecture. | L1 1:23:07 |
| Aminoglycosides | “A very good example of a concentration dependent killer” — which is why dosing moved from every 8 hours to every 24. | L1 1:24:37 |
| Aminoglycosides | “The first example we’re seeing of a bactericidal protein synthesis inhibitor” — the exception to the rule that protein synthesis inhibitors are static. | L1 1:24:59 |
| Drug levels | Give three or four doses before checking a level, so you are at steady state. | L1 1:27:33 |
| Linezolid | “Notable toxicity… thrombocytopenia”, plus interactions with antidepressants. | L1 1:28:31 |
| Daptomycin | “Notable toxicity… myalgias, muscle pain.” | L1 1:30:21 |
| Daptomycin | “Notable toxicity there, we haven’t really seen anywhere else yet” — and it cannot be used in pneumonia. | L1 1:31:08 |
| Fluoroquinolones | They worsen cognition in elderly patients — “one notable set of antibiotics which can worsen that cognition.” | L1 1:35:42 |
| Fluoroquinolones | Tendon injury is “more notable in children, so like less than 16.” | L1 1:36:42 |
| Moxifloxacin | “The notable unique thing about moxifloxacin compared to the others” — no pseudomonal cover, and not for urinary tract infection. | L1 1:39:19 |
| Clindamycin | “This one in particular is notable for being the most likely to cause” C. difficile. | L1 1:41:58 |
| Trimethoprim/sulfamethoxazole | “This is notable” — PJP pneumonia, the Pneumocystis indication. | L1 1:44:47 |
| Trimethoprim/sulfamethoxazole | Rash — “this one is much more likely to cause rash… very notable from that standpoint.” | L1 1:45:17 |
| Trimethoprim/sulfamethoxazole | The notable interactions run through CYP2C9 inhibition — above all warfarin. | L1 1:46:26 |
| Metronidazole | “Really notable for having mostly just anaerobic coverage.” | L1 1:47:49 |
| Metronidazole | “The other really notable thing… is there’s an interaction here with alcohol or ethanol.” | L1 1:48:34 |
| Amphotericin B | “A pretty notable one” — it forms a pore in the ergosterol membrane. | L1 1:58:30 |
| Azoles | “Anytime you see the azole… you kind of know it fits in” — the naming tells you the class. | L1 2:08:46 |
| Ceftaroline | “Just notable about it” — it does carry MRSA coverage, but he would not start with it for known MRSA when tried-and-true options exist. | L1 56:29 |
| Polymyxins | “It’s just a nasty set of drugs. Really rough on the kidneys too” — nephrotoxicity, neurotoxicity, and neuromuscular blockade interacting with paralytics. “Don’t use it too often.” | L1 1:52:42 |
| Fluconazole | “Watch out for CYP3A4 interactions for sure” — 3A4 being the interaction he says matters for this exam. | L1 2:07:24 |
| Acyclovir | The crystals pierce the renal tubules — “good hydration, really critical there.” Then CNS seizures and delirium, and bone marrow suppression because it hits rapidly dividing cells. | L1 2:18:28 |
| Isotretinoin | “One of the most notable examples of a REMS program” — this is iPledge, and he ties it straight to the pregnancy contraindication. | L2 39:36 |
| Topical corticosteroids | The gold standard for atopic dermatitis — selection then turns on the product, and the severity and site of disease. | L2 54:20 |